Streetbeat News

Analyst Ratings

TBRG

TruBridge (NASDAQ:TBRG) has received mixed analyst ratings, with all five analysts being somewhat bullish. The average 12-month price target has increased by 4.69% to $13.4. TruBridge shows positive revenue growth but faces challenges with a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 2:01 pm

HROW

Harrow (NASDAQ:HROW) has received varied analyst ratings over the past three months, with a shift towards bullish sentiment. Analysts have raised their price targets, with the current average target at $52.5, up 36.36% from the previous $38.50. Harrow, an eyecare pharmaceutical company, has shown strong revenue growth but faces challenges with its ROE and ROA.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 2:01 pm

RCM

Eight analysts have provided ratings on R1 RCM (NASDAQ:RCM) over the past three months, with a mix of bullish, neutral, and bearish sentiments. The average 12-month price target has decreased by 6.33% to $14.94. R1 RCM's financials show revenue growth but challenges in profitability and returns.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 2:01 pm

FHI

In the past three months, six analysts have provided ratings for Federated Hermes (NYSE:FHI), with a mix of somewhat bullish and indifferent sentiments. The average 12-month price target is $37.17, slightly down from $37.50. Analysts have adjusted their ratings and price targets based on market conditions and company performance. Federated Hermes faces challenges with revenue growth, net margin, ROE, and ROA, but maintains a balanced debt approach.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 2:00 pm

TBRG

Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on TruBridge (NASDAQ:TBRG) and maintained a price target of $13.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 2:00 pm

AFRM

Analysts have provided diverse evaluations of Affirm Holdings (NASDAQ:AFRM) over the past three months, with a mix of bullish and bearish outlooks. The average 12-month price target has increased by 9.19% to $46.1. Despite strong revenue growth, Affirm faces challenges with profitability and financial leverage.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 2:00 pm

ATYR

Wells Fargo has initiated coverage on aTyr Pharma with an Overweight rating and set a price target of $17.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 1:59 pm

SGRY

Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on Surgery Partners (NASDAQ:SGRY) and maintained a price target of $43.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 1:55 pm

CHRW

UBS analyst Thomas Wadewitz has upgraded C.H. Robinson Worldwide (NASDAQ:CHRW) from Neutral to Buy and increased the price target from $100 to $140.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 1:55 pm

MBLY

UBS analyst Joseph Spak has downgraded Mobileye Global (NASDAQ:MBLY) from Buy to Neutral and reduced the price target from $20 to $14.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 1:52 pm